Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Zitel-ZITL What's Happening -- Ignore unavailable to you. Want to Upgrade?

To: CMason who wrote (12424)	10/31/1997 1:33:00 PM
From: John Kratus	Read Replies (2) \| Respond to of 18263

Wasn't Biotime recommended by Individual Investor? The kiss of death!

To: CMason who wrote (12424)	10/31/1997 4:42:00 PM
From: Jim Roof	Read Replies (1) \| Respond to of 18263

Must chime in here. BTIM has a 1.4M payment from Abbott Labs and a royalty structure for sales that pays up to 36%. Biotime Inc. will incur marketing costs and sales costs of approximately $0.00 on potential sales into the hundreds of millions. Abbott is doing all the investing here while this little company of 13 could actually afford to lay off all but one employee whose sole job would be to get the checks and run them to the bank. I know this is sounding rather trite and somewhat sarcastic, but Biotime's phase III trials went reportedly without a hitch and the basic components of Hextend (Biotime's product) are so well known in medicine that the Phase I and Phase II trials were not even needed. Nonetheless, Biotime has sufficiently protected their product with patents. Abbott's relationship to Biotime will probably aid Biotime's FDA approval. If you want to short it I will be the first to encourage you to do just that. However, check out the current short interest (it has been historically around 15%). And keep in mind that these short shares represent to me nothing more than guaranteed shares purchased in the very near future. Consider also the confidence in Biotime shown by Abbott, who by the way already produces and markets what will be Hextend's leading competing product - Hespan. So, not only will Abbott be able to roll out a superior product, they will simultaneously be able to remove a large portion of the competition. Oh, one more thing. Do some research. Hextend is a blood plasma extender whose primary use would be to stabilize trauma patients who have lost large quantities of blood and face the danger of shock related such volume loss. It would also be used for surgery. Studies have shown that shock and the effects of volume loss are reduced even when the blood mixture is one part whole blood to 2 parts Hextend. Hextend also addresses the clotting problems (lack of clotting) found with other solutions and risks associated with typing/infections when using transfused whole blood. It also reduces edema which is common with saline solutions. Jim